Clin2
NCT07889999Possibly a fitRecruiting

Ursosan for liver fat in Kazakhstan

Metabolic Dysfunction-Associated Steatotic Liver Disease

This study looks at how well Ursosan, a medicine for liver problems, works in people with fatty liver disease linked to metabolic issues like obesity or diabetes. It may help improve liver health and reduce fat in the liver.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
420 people
Ages
18 years to 65 years
Study type
Observational

Who can take part

  • You are between 18 and 65 years old
  • You have been told you have fatty liver disease, confirmed by an ultrasound, CT scan, or MRI
  • You have at least one metabolic condition such as being overweight, having diabetes or prediabetes, high cholesterol, or high blood pressure
  • If you are in the treatment part of the study, you must have higher than normal liver enzymes (ALT) and be taking Ursosan as prescribed by your doctor, no more than 4 weeks before joining
  • You must not have certain other liver diseases, be pregnant, or have certain other conditions listed in the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06935994Recruiting· Phase 2
Aspirin for Fatty Liver Disease (MASLD)

This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.

Taichung, Taiwan
NCT07850063Not yet recruiting· Phase 3
Heart and liver health study for people with overweight

This study tests a new medicine called survodutide to see if it can improve heart function and structure in people who are overweight and have fatty liver disease. It may help reduce risks related to heart problems.

Peoria, Arizona
NCT07878091Not yet recruiting· Phase 2
Kylo-0603 for fatty liver disease

This trial tests an experimental pill called Kylo-0603 for fatty liver disease (MASLD). The pill may help reduce fat build-up in the liver and improve liver health. It is for people who are overweight or obese with a confirmed fatty liver, but who do not have cirrhosis or other liver conditions.

Beijing, Beijing Municipality
NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients

This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.

Angers
NCT06764056Not yet recruiting
Liver fat study for people with obesity

This study looks at liver fat and how to manage it in people with obesity. It may help find better ways to treat fatty liver disease.

Québec, Quebec
NCT07025980Not yet recruiting· Phase 2
Probiotics for fatty liver disease

This study tests whether taking a probiotic supplement (a mix of helpful bacteria) can improve liver health in people with fatty liver disease linked to metabolic syndrome. It may help lower liver enzymes and reduce fat buildup in the liver.

Šibenik, Croatia

Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.